Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2775064 | 0.83 | NAPRT (0.62) | NAPRTCYP1A2CYP3A4CYP2C9CHRNB2 | |
| SCHEMBL8020607 | 0.82 | HSD11B1 (0.50) | NAPRTCHRNB2CHRNA4CHRNA7RIPK1 | |
| SCHEMBL11293565 | 0.80 | NAPRT (0.48) | NAPRTCYP1A2CYP3A4CYP2C9CHRNB2 | |
| SCHEMBL16320737 | 0.80 | HDAC4 (0.48) | CYP19A1GAA | |
| SCHEMBL18505713 | 0.80 | HDAC4 (0.42) | NAPRTPKMKMT2A | |
| SCHEMBL361027 | 0.80 | ALOX5 (0.53) | LMNA | |
| SCHEMBL12424117 | 0.78 | NAPRT (0.59) | NAPRTCYP1A2CYP3A4CYP2C9CHRNB2 | |
| SCHEMBL178130 | 0.77 | NAPRT (0.62) | NAPRTCYP1A2CYP3A4CYP2C9PKM | |
| SCHEMBL29466814 | 0.77 | NAPRT (0.62) | NAPRTCYP1A2CYP3A4CYP2C9PKM | |
| SCHEMBL4540688 | 0.76 | NAPRT (0.57) | NAPRTCYP1A2CYP3A4CYP2C9CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522618-B2 | Copper complexes for treatment of neurodegenerative disorders | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2026-01-13 | — | — | US | disclosed |
| US-20240368195-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS THERAPY DEVELOPMENT INST (US) | 2024-11-07 | — | — | US | disclosed |
| US-12012422-B2 | Copper complexes for treatment of neurodegenerative disorders | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2024-06-18 | — | — | US | disclosed |
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | PROTEGO BIOPHARMA, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | PROTEGO BIOPHARMA, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | PROTEGO BIOPHARMA, INC. | 2023-09-14 | — | — | US | disclosed |
| EP-4204399-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS Therapy Development Institute (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116234800-A | Copper complexes for the treatment of neurodegenerative disorders | ALS治疗发展学会 | 2023-06-06 | — | — | CN | disclosed |
| US-20230054997-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS THERAPY DEVELOPMENT INSTITUTE, | 2023-02-23 | — | — | US | disclosed |
| US-20230054997-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS THERAPY DEVELOPMENT INSTITUTE, | 2023-02-23 | — | — | US | disclosed |
| US-8084473-B2 | Heterocyclic compounds with affinity to muscarinic receptors | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-12-27 | — | — | US | disclosed |
| EP-1966146-B1 | 4,5-DIHYDRO- (1H)-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR MODULATORS | ABBOTT HEALTHCARE PRODUCTS BV (NL) | 2011-03-02 | — | — | EP | disclosed |
| US-20090018160-A1 | Heterocyclic Compounds with Affinity to Muscarinic Receptors | ABBVIE B.V. (NL) | 2009-01-15 | — | — | US | disclosed |
| US-20090018160-A1 | Heterocyclic Compounds with Affinity to Muscarinic Receptors | ABBVIE B.V. (NL) | 2009-01-15 | — | — | US | disclosed |
| US-20090018160-A1 | Heterocyclic Compounds with Affinity to Muscarinic Receptors | ABBVIE B.V. (NL) | 2009-01-15 | — | — | US | disclosed |
| WO-2008129054-A2 | HETEROCYCLIC COMPOUNDS WITH AFFINITY TO MUSCARINIC RECEPTORS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-10-30 | — | — | WO | disclosed |
| EP-1966146-A1 | 4,5-DIHYDRO- (1H)-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR MODULATORS | Solvay Pharmaceuticals B.V. (NL) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071662-A1 | 4,5-DIHYDRO- (1H)-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR MODULATORS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2007-06-28 | — | — | WO | disclosed |
| US-20070142362-A1 | 4,5-Dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators | SOLVAY PHARMACEUTICALS B.V. | 2007-06-21 | — | — | US | disclosed |
| US-6156767-A | Antagonists of gonadotropin releasing hormone | MERCK & CO., INC. (US) | 2000-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | TTR, TTPA, TNNC1 | NAPRT 1452/4885CYP1A2 4425/4885CYP3A4 4010/4885 |
| US-20070142362-A1 | 4,5-Dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators | CNR1, CNR2, GPR55 | NAPRT 1323/4885CYP1A2 337/4885CYP3A4 322/4885 |
| US-12012422-B2 | Copper complexes for treatment of neurodegenerative disorders | SOD1, SMN1; SMN2, CLN6 | NAPRT 2997/4885CYP1A2 3778/4885CYP3A4 4471/4885 |
| US-20230054997-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SOD1, SMN1; SMN2, CLN6 | NAPRT 2997/4885CYP1A2 3778/4885CYP3A4 4471/4885 |
| US-20240368195-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SOD1, SMN1; SMN2, CLN6 | NAPRT 2997/4885CYP1A2 3778/4885CYP3A4 4471/4885 |
| US-20090018160-A1 | Heterocyclic Compounds with Affinity to Muscarinic Receptors | CHRM3, CHRM2, CHRM1 | NAPRT 2265/4885CYP1A2 825/4885CYP3A4 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.